Therapeutic Drug Monitoring Market By Drugs (Antibiotics, Cardiac Drugs, Antiepileptics, Bronchodilators, Immunosuppressants, Anti-cancer drugs, Psychiatric drugs, Antiarrythmics, Others); By Products (Consumables, Equipment (Immunoassay Analyzers, Chromatography and MS Detectors, Others) Others); By Technology (Fluorescence Immunoassay, Chemiluminescent Immunoassays, Radioimmunassay, Thin Layer Chromatography, Radio immuno assay, Enzyme immune assay, Spectrophotometry and Fluorimetry, Others); By End Users(Hospitals & Clinics, Diagnostic centers, Research institutes, Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027

Report ID :AMI-686 | Category : Healthcare | Published Date : October, 2020 | Pages : 402 | Format :PDF

Industry Trends

Therapeutic drug monitoring (TDM) can be termed as the management of the drug regimen based on the concentration of the drug in the serum, plasma or whole blood of the patient. In TDM, a precise and reliable measure of the plasma concentration of a specific medicine is obtained initially. Later, the sample is used for the interpretation of the concentration-effect relationship in patients. This data is then used for the calculation of a personalized dose adjustment for the patient. Therapeutic drug monitoring is generally used with drugs having features like marked pharmacokinetic (movement of drug through body) variability, narrow therapeutic index (ratio that compares the blood concentration at which a drug becomes toxic), amongst others. TDM is witnessing high demand amidst the growth of chronic diseases worldwide. World Health Organization states that chronic diseases such as cardiovascular diseases, respiratory diseases, cancer, diabetes, etc., will account for 60% of global disease burden, and 73% of all deaths globally by 2020. These diseases mostly require continuous medications. This, in turn creates a need for maintaining a steady concentration of drugs in the blood streams of the patient throughout the patient's life. Therapeutic drug monitoring assist medical professionals in identifying appropriate drug dosage for patients affected by chronic diseases. It is also essential for the determination of immunosuppressive drug concentrations in treatment of immune-mediated diseases. Thus, the significant increase in chronic diseases which require constant drug concentration monitoring is driving the growth of the therapeutic drug monitoring market across the globe.

Clinical assessment of patients through therapeutic drug monitoring provides information with respect to the improvement post drug intake, and possible drug-related side effects. However, the lack of awareness regarding the benefits of drug monitoring amongst the low and middle income population in the developing countries is hindering the growth of the global therapeutic drug monitoring market. World Health Organization states that reduced survival years due to medication-related errors in developing nations is almost twice as that of the developed nations. Other factors such as inaccuracies in the measurement of plasma concentration values and the lack of technical skills that are necessary for the interpretation of plasma concentration value in human beings are few factors restraining the growth of the global therapeutic drug monitoring market.

Government bodies and health organizations around the globe are initiating programs to spread awareness on drug therapy management for reducing medication-associated health hazards amongst individuals. Organizations across the world are also encouraging the use of therapeutic drug monitoring. For instance, World Health Organization launched a program named Global Patient Safety Challenge on Medication Safety in March 2017. The program is aimed at improving the medicine prescription and consumption methods, as well as creating awareness among patients about the risks associated with the improper use of medication. Similarly, government bodies in Australia, the U.S, India, Malaysia, etc., are promoting the adoption of therapeutic drug monitoring. Therefore, these government initiatives that aid in the familiarization of TDM are anticipated to propel the growth of the global therapeutic drug monitoring market in the coming years.

The recent outbreak of COVID-19 pandemic has led to more than 33.5 million reported cases of infection, and death of around 1 million people across the globe. The pandemic has created a high demand for an effective plan for the creation of a vaccine as well as the discovery of drugs that aid in patient recovery. Researchers are experimenting with a variety of potential drugs that are suitable for COVID-19 recovery. For instance, companies such as Astellas, AstraZeneca, Johnson & Johnson, Novartis, amongst others are conducting research to develop effective medicine for Coronavirus infection. Assessmet-based studies of dose tolerance and dose response in patients are an integral part of the drug development process, and require insightful analysis for dosage optimization. Pharmacokinetic and pharmacodynamics studies are also involved in these phases. They are performed through therapeutic drug monitoring. Thus, the demand for analytical studies of pharmaceutical drugs under development to curb the COVID-19 outbreak is expected to boost the growth of global therapeutic drug monitoring market.

Drugs Outlook:

Studies show that cardiovascular diseases are the leading cause of deaths across the globe, with over 17.9 million lives being claimed each year. The number of diseases are expected to increase in the coming years as a result of added stress amongst individuals. The prevalence of cardiovascular diseases has inflated the demand for cardiac drugs for the treatment conditions such as of angina, arrhythmias and congestive failure. Digoxin or Lanxin is a commonly prescribed drug for congestive failure and it is therapeutically monitored for assessing the pharmacokinetics of patients. Thus, sudden growth in the number of cardiovascular diseases, coupled with the need for analysing the toxicity of drugs used in the treatment is driving the share of cardiac drugs in the global therapeutic drug monitoring market.

Technology Outlook:

Based on the type of technology, fluorescence immunoassay accounted for a significant share in the global therapeutic drug monitoring market in 2018. This can be attributed to its high specificity, accuracy and precision. The technology is used in numerous medical care facilities for the measurement of various compounds, especially pharmaceutical drugs in patients. Fluorescence immunoassays with features like low cost light source compatibility, stable fluorophores, stable solid state light detectors and microchips for processing data are being developed by the market participants. For instance, the fluorescence immunoassays of Quidel Corporation has microprocessors which facilitate accurate testing and reduce misinterpretation of data. Thus, higher levels of accuracy, reliability and ease of handling are few of the factors driving the share of fluorescence immunoassay technology in the therapeutic drug monitoring market across the globe.

Regional Outlook:

North America region registered the highest share in global therapeutic drug monitoring market in 2018, owing to the high presence of geriatric population. Statistics of the U.S. Census Bureau stated more than 54 million Americans were 65 years of age or older, in July 2019. The geriatric population is highly prone to adverse drug reactions, drug interactions and chronic medical conditions, which drastically increases the challenges associated with drug therapy management. Thus, the high risk of drug toxicity among geriatric population is creating demand for therapeutic drug monitoring to verify patient compliance with drug regimens in the North American region.

In terms of revenue, global therapeutic drug monitoring market was valued at US$ 1465.62 Mn in 2018 and is anticipated to grow at a CAGR of 6.27% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.

Global Therapeutic Drug Monitoring Market Revenue & Forecast, (US$ Million), 2015 – 2027

Global Therapeutic Drug Monitoring Market

Competitive Landscape

The report provides both, qualitative and quantitative research of therapeutic drug monitoring market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Some of the players operating in the therapeutic drug monitoring market are Abbot, Agilent Technologies, apDia Group, ARK Diagnostics, Inc., Beckman Coulter, Inc., bioMérieux S.A., Bio-Rad Laboratories, Inc., BioTeZ Berlin Buch GmbH, BÜHLMANN, Chromsystems Instruments & Chemicals GmbH, Exagen, Inc., F. Hoffmann-La Roche Ltd, Hamilton Company, Immundiagnostik AG, Quest Diagnostics Incorporated, Randox Laboratories Ltd., R-Biopharm AG, SEKISUI CHEMICAL CO., LTD., Siemens Healthcare Private Limited, THERADIAG, Thermo Fisher Scientific Inc. and UTAKamongst others.

Global Therapeutic Drug MonitoringMarket:

By Drugs

  • Antibiotics
  • Cardiac Drugs
  • Antiepileptics
  • Bronchodilators
  • Immunosuppressants
  • Anti-cancer drugs
  • Psychiatric drugs
  • Antiarrythmics
  • Others

By Products

  • Consumables
  • Equipment
    • Immunoassay Analyzers
    • Chromatography and MS Detectors
    • Others
  • Others

By Technology

  • Fluorescence Immunoassay
  • Chemiluminescent Immunoassays
  • Radioimmunassay
  • Thin Layer Chromatography
  • Radio immuno assay
  • Enzyme immune assay
  • Spectrophotometry and Fluorimetry
  • Others

By End Users

  • Hospitals & Clinics
  • Diagnostic centers
  • Research institutes
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic Countries
      • Denmark
      • Finland
      • Iceland
      • Sweden
      • Norway
    • Benelux Union
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Table of Contents

 


1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2013 - 2017

1.2.2. Base Year: 2018

1.2.3. Forecast Years: 2019 – 2027

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of Therapeutic Drug Monitoring Market

6. Market Synopsis:  Therapeutic Drug Monitoring Market

7. Therapeutic Drug Monitoring Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.3. Trends in Therapeutic Drug Monitoring Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Therapeutic Drug Monitoring Market

7.6. Analysis on Impact of COVID-19 on Therapeutic Drug Monitoring Market

8. Global Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 – 2027

8.1. Overview

8.1.1. Global Therapeutic Drug Monitoring Market Revenue (US$ Mn)

8.2. Global Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

8.2.1. Antibiotics

8.2.1.1. Definition

8.2.1.2. Market Estimation and Penetration, 2013 – 2018

8.2.1.3. Market Forecast, 2019 – 2027

8.2.1.4. Compound Annual Growth Rate (CAGR)

8.2.1.5. Regional Bifurcation

8.2.1.5.1. North America

8.2.1.5.1.1. Market Estimation, 2013 – 2018

8.2.1.5.1.2. Market Forecast, 2019 – 2027

8.2.1.5.2. Europe

8.2.1.5.2.1. Market Estimation, 2013 – 2018

8.2.1.5.2.2. Market Forecast, 2019 – 2027

8.2.1.5.3. Asia Pacific

8.2.1.5.3.1. Market Estimation, 2013 – 2018

8.2.1.5.3.2. Market Forecast, 2019 – 2027

8.2.1.5.4. Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2013 – 2018

8.2.1.5.4.2. Market Forecast, 2019 – 2027

8.2.1.5.5. Latin America

8.2.1.5.5.1. Market Estimation, 2013 – 2018

8.2.1.5.5.2. Market Forecast, 2019 – 2027

8.2.2. Cardiac Drugs

8.2.2.1. Definition

8.2.2.2. Market Estimation and Penetration, 2013 – 2018

8.2.2.3. Market Forecast, 2019 – 2027

8.2.2.4. Compound Annual Growth Rate (CAGR)

8.2.2.5. Regional Bifurcation

8.2.2.5.1. North America

8.2.2.5.1.1. Market Estimation, 2013 – 2018

8.2.2.5.1.2. Market Forecast, 2019 – 2027

8.2.2.5.2. Europe

8.2.2.5.2.1. Market Estimation, 2013 – 2018

8.2.2.5.2.2. Market Forecast, 2019 – 2027

8.2.2.5.3. Asia Pacific

8.2.2.5.3.1. Market Estimation, 2013 – 2018

8.2.2.5.3.2. Market Forecast, 2019 – 2027

8.2.2.5.4. Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2013 – 2018

8.2.2.5.4.2. Market Forecast, 2019 – 2027

8.2.2.5.5. Latin America

8.2.2.5.5.1. Market Estimation, 2013 – 2018

8.2.2.5.5.2. Market Forecast, 2019 – 2027

8.2.3. Antiepileptics

8.2.3.1. Definition

8.2.3.2. Market Estimation and Penetration, 2013 – 2018

8.2.3.3. Market Forecast, 2019 – 2027

8.2.3.4. Compound Annual Growth Rate (CAGR)

8.2.3.5. Regional Bifurcation

8.2.3.5.1. North America

8.2.3.5.1.1. Market Estimation, 2013 – 2018

8.2.3.5.1.2. Market Forecast, 2019 – 2027

8.2.3.5.2. Europe

8.2.3.5.2.1. Market Estimation, 2013 – 2018

8.2.3.5.2.2. Market Forecast, 2019 – 2027

8.2.3.5.3. Asia Pacific

8.2.3.5.3.1. Market Estimation, 2013 – 2018

8.2.3.5.3.2. Market Forecast, 2019 – 2027

8.2.3.5.4. Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2013 – 2018

8.2.3.5.4.2. Market Forecast, 2019 – 2027

8.2.3.5.5. Latin America

8.2.3.5.5.1. Market Estimation, 2013 – 2018

8.2.3.5.5.2. Market Forecast, 2019 – 2027

8.2.4. Bronchodilators

8.2.4.1. Definition

8.2.4.2. Market Estimation and Penetration, 2013 – 2018

8.2.4.3. Market Forecast, 2019 – 2027

8.2.4.4. Compound Annual Growth Rate (CAGR)

8.2.4.5. Regional Bifurcation

8.2.4.5.1. North America

8.2.4.5.1.1. Market Estimation, 2013 – 2018

8.2.4.5.1.2. Market Forecast, 2019 – 2027

8.2.4.5.2. Europe

8.2.4.5.2.1. Market Estimation, 2013 – 2018

8.2.4.5.2.2. Market Forecast, 2019 – 2027

8.2.4.5.3. Asia Pacific

8.2.4.5.3.1. Market Estimation, 2013 – 2018

8.2.4.5.3.2. Market Forecast, 2019 – 2027

8.2.4.5.4. Middle East and Africa

8.2.4.5.4.1. Market Estimation, 2013 – 2018

8.2.4.5.4.2. Market Forecast, 2019 – 2027

8.2.4.5.5. Latin America

8.2.4.5.5.1. Market Estimation, 2013 – 2018

8.2.4.5.5.2. Market Forecast, 2019 – 2027

8.2.5. Immunosuppressants

8.2.5.1. Definition

8.2.5.2. Market Estimation and Penetration, 2013 – 2018

8.2.5.3. Market Forecast, 2019 – 2027

8.2.5.4. Compound Annual Growth Rate (CAGR)

8.2.5.5. Regional Bifurcation

8.2.5.5.1. North America

8.2.5.5.1.1. Market Estimation, 2013 – 2018

8.2.5.5.1.2. Market Forecast, 2019 – 2027

8.2.5.5.2. Europe

8.2.5.5.2.1. Market Estimation, 2013 – 2018

8.2.5.5.2.2. Market Forecast, 2019 – 2027

8.2.5.5.3. Asia Pacific

8.2.5.5.3.1. Market Estimation, 2013 – 2018

8.2.5.5.3.2. Market Forecast, 2019 – 2027

8.2.5.5.4. Middle East and Africa

8.2.5.5.4.1. Market Estimation, 2013 – 2018

8.2.5.5.4.2. Market Forecast, 2019 – 2027

8.2.5.5.5. Latin America

8.2.5.5.5.1. Market Estimation, 2013 – 2018

8.2.5.5.5.2. Market Forecast, 2019 – 2027

8.2.6. Anti-cancer drugs

8.2.6.1. Definition

8.2.6.2. Market Estimation and Penetration, 2013 – 2018

8.2.6.3. Market Forecast, 2019 – 2027

8.2.6.4. Compound Annual Growth Rate (CAGR)

8.2.6.5. Regional Bifurcation

8.2.6.5.1. North America

8.2.6.5.1.1. Market Estimation, 2013 – 2018

8.2.6.5.1.2. Market Forecast, 2019 – 2027

8.2.6.5.2. Europe

8.2.6.5.2.1. Market Estimation, 2013 – 2018

8.2.6.5.2.2. Market Forecast, 2019 – 2027

8.2.6.5.3. Asia Pacific

8.2.6.5.3.1. Market Estimation, 2013 – 2018

8.2.6.5.3.2. Market Forecast, 2019 – 2027

8.2.6.5.4. Middle East and Africa

8.2.6.5.4.1. Market Estimation, 2013 – 2018

8.2.6.5.4.2. Market Forecast, 2019 – 2027

8.2.6.5.5. Latin America

8.2.6.5.5.1. Market Estimation, 2013 – 2018

8.2.6.5.5.2. Market Forecast, 2019 – 2027

8.2.7. Psychiatric drugs

8.2.7.1. Definition

8.2.7.2. Market Estimation and Penetration, 2013 – 2018

8.2.7.3. Market Forecast, 2019 – 2027

8.2.7.4. Compound Annual Growth Rate (CAGR)

8.2.7.5. Regional Bifurcation

8.2.7.5.1. North America

8.2.7.5.1.1. Market Estimation, 2013 – 2018

8.2.7.5.1.2. Market Forecast, 2019 – 2027

8.2.7.5.2. Europe

8.2.7.5.2.1. Market Estimation, 2013 – 2018

8.2.7.5.2.2. Market Forecast, 2019 – 2027

8.2.7.5.3. Asia Pacific

8.2.7.5.3.1. Market Estimation, 2013 – 2018

8.2.7.5.3.2. Market Forecast, 2019 – 2027

8.2.7.5.4. Middle East and Africa

8.2.7.5.4.1. Market Estimation, 2013 – 2018

8.2.7.5.4.2. Market Forecast, 2019 – 2027

8.2.7.5.5. Latin America

8.2.7.5.5.1. Market Estimation, 2013 – 2018

8.2.7.5.5.2. Market Forecast, 2019 – 2027

8.2.8. Antiarrythmics

8.2.8.1. Definition

8.2.8.2. Market Estimation and Penetration, 2013 – 2018

8.2.8.3. Market Forecast, 2019 – 2027

8.2.8.4. Compound Annual Growth Rate (CAGR)

8.2.8.5. Regional Bifurcation

8.2.8.5.1. North America

8.2.8.5.1.1. Market Estimation, 2013 – 2018

8.2.8.5.1.2. Market Forecast, 2019 – 2027

8.2.8.5.2. Europe

8.2.8.5.2.1. Market Estimation, 2013 – 2018

8.2.8.5.2.2. Market Forecast, 2019 – 2027

8.2.8.5.3. Asia Pacific

8.2.8.5.3.1. Market Estimation, 2013 – 2018

8.2.8.5.3.2. Market Forecast, 2019 – 2027

8.2.8.5.4. Middle East and Africa

8.2.8.5.4.1. Market Estimation, 2013 – 2018

8.2.8.5.4.2. Market Forecast, 2019 – 2027

8.2.8.5.5. Latin America

8.2.8.5.5.1. Market Estimation, 2013 – 2018

8.2.8.5.5.2. Market Forecast, 2019 – 2027

8.2.9. Others

8.2.9.1. Definition

8.2.9.2. Market Estimation and Penetration, 2013 – 2018

8.2.9.3. Market Forecast, 2019 – 2027

8.2.9.4. Compound Annual Growth Rate (CAGR)

8.2.9.5. Regional Bifurcation

8.2.9.5.1. North America

8.2.9.5.1.1. Market Estimation, 2013 – 2018

8.2.9.5.1.2. Market Forecast, 2019 – 2027

8.2.9.5.2. Europe

8.2.9.5.2.1. Market Estimation, 2013 – 2018

8.2.9.5.2.2. Market Forecast, 2019 – 2027

8.2.9.5.3. Asia Pacific

8.2.9.5.3.1. Market Estimation, 2013 – 2018

8.2.9.5.3.2. Market Forecast, 2019 – 2027

8.2.9.5.4. Middle East and Africa

8.2.9.5.4.1. Market Estimation, 2013 – 2018

8.2.9.5.4.2. Market Forecast, 2019 – 2027

8.2.9.5.5. Latin America

8.2.9.5.5.1. Market Estimation, 2013 – 2018

8.2.9.5.5.2. Market Forecast, 2019 – 2027

8.3. Key Segment for Channeling Investments

8.3.1. By Drugs

9. Global Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 – 2027

9.1. Overview

9.2. Global Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

9.2.1. Consumables

9.2.1.1. Definition

9.2.1.2. Market Estimation and Penetration, 2013 – 2018

9.2.1.3. Market Forecast, 2019 – 2027

9.2.1.4. Compound Annual Growth Rate (CAGR)

9.2.1.5. Regional Bifurcation

9.2.1.5.1. North America

9.2.1.5.1.1. Market Estimation, 2013 – 2018

9.2.1.5.1.2. Market Forecast, 2019 – 2027

9.2.1.5.2. Europe

9.2.1.5.2.1. Market Estimation, 2013 – 2018

9.2.1.5.2.2. Market Forecast, 2019 – 2027

9.2.1.5.3. Asia Pacific

9.2.1.5.3.1. Market Estimation, 2013 – 2018

9.2.1.5.3.2. Market Forecast, 2019 – 2027

9.2.1.5.4. Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2013 – 2018

9.2.1.5.4.2. Market Forecast, 2019 – 2027

9.2.1.5.5. Latin America

9.2.1.5.5.1. Market Estimation, 2013 – 2018

9.2.1.5.5.2. Market Forecast, 2019 – 2027

9.2.2. Equipment (Definition, Market Estimation and Penetration, 2013 – 2018, Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Immunoassay Analyzers, Chromatography and MS Detectors, Others)

9.2.2.1. Immunoassay Analyzers

9.2.2.2. Chromatography and MS Detectors

9.2.2.3. Others

9.2.3. Others

9.2.3.1. Definition

9.2.3.2. Market Estimation and Penetration, 2013 – 2018

9.2.3.3. Market Forecast, 2019 – 2027

9.2.3.4. Compound Annual Growth Rate (CAGR)

9.2.3.5. Regional Bifurcation

9.2.3.5.1. North America

9.2.3.5.1.1. Market Estimation, 2013 – 2018

9.2.3.5.1.2. Market Forecast, 2019 – 2027

9.2.3.5.2. Europe

9.2.3.5.2.1. Market Estimation, 2013 – 2018

9.2.3.5.2.2. Market Forecast, 2019 – 2027

9.2.3.5.3. Asia Pacific

9.2.3.5.3.1. Market Estimation, 2013 – 2018

9.2.3.5.3.2. Market Forecast, 2019 – 2027

9.2.3.5.4. Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2013 – 2018

9.2.3.5.4.2. Market Forecast, 2019 – 2027

9.2.3.5.5. Latin America

9.2.3.5.5.1. Market Estimation, 2013 – 2018

9.2.3.5.5.2. Market Forecast, 2019 – 2027

9.3. Key Segment for Channeling Investments

9.3.1. By Products

10. Global Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 – 2027

10.1. Overview

10.2. Global Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

10.2.1. Fluorescence Immunoassay

10.2.1.1. Definition

10.2.1.2. Market Estimation and Penetration, 2013 – 2018

10.2.1.3. Market Forecast, 2019 – 2027

10.2.1.4. Compound Annual Growth Rate (CAGR)

10.2.1.5. Regional Bifurcation

10.2.1.5.1. North America

10.2.1.5.1.1. Market Estimation, 2013 – 2018

10.2.1.5.1.2. Market Forecast, 2019 – 2027

10.2.1.5.2. Europe

10.2.1.5.2.1. Market Estimation, 2013 – 2018

10.2.1.5.2.2. Market Forecast, 2019 – 2027

10.2.1.5.3. Asia Pacific

10.2.1.5.3.1. Market Estimation, 2013 – 2018

10.2.1.5.3.2. Market Forecast, 2019 – 2027

10.2.1.5.4. Middle East and Africa

10.2.1.5.4.1. Market Estimation, 2013 – 2018

10.2.1.5.4.2. Market Forecast, 2019 – 2027

10.2.1.5.5. Latin America

10.2.1.5.5.1. Market Estimation, 2013 – 2018

10.2.1.5.5.2. Market Forecast, 2019 – 2027

10.2.2. Chemiluminescent Immunoassays

10.2.2.1. Definition

10.2.2.2. Market Estimation and Penetration, 2013 – 2018

10.2.2.3. Market Forecast, 2019 – 2027

10.2.2.4. Compound Annual Growth Rate (CAGR)

10.2.2.5. Regional Bifurcation

10.2.2.5.1. North America

10.2.2.5.1.1. Market Estimation, 2013 – 2018

10.2.2.5.1.2. Market Forecast, 2019 – 2027

10.2.2.5.2. Europe

10.2.2.5.2.1. Market Estimation, 2013 – 2018

10.2.2.5.2.2. Market Forecast, 2019 – 2027

10.2.2.5.3. Asia Pacific

10.2.2.5.3.1. Market Estimation, 2013 – 2018

10.2.2.5.3.2. Market Forecast, 2019 – 2027

10.2.2.5.4. Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2013 – 2018

10.2.2.5.4.2. Market Forecast, 2019 – 2027

10.2.2.5.5. Latin America

10.2.2.5.5.1. Market Estimation, 2013 – 2018

10.2.2.5.5.2. Market Forecast, 2019 – 2027

10.2.3. Radioimmunassay

10.2.3.1. Definition

10.2.3.2. Market Estimation and Penetration, 2013 – 2018

10.2.3.3. Market Forecast, 2019 – 2027

10.2.3.4. Compound Annual Growth Rate (CAGR)

10.2.3.5. Regional Bifurcation

10.2.3.5.1. North America

10.2.3.5.1.1. Market Estimation, 2013 – 2018

10.2.3.5.1.2. Market Forecast, 2019 – 2027

10.2.3.5.2. Europe

10.2.3.5.2.1. Market Estimation, 2013 – 2018

10.2.3.5.2.2. Market Forecast, 2019 – 2027

10.2.3.5.3. Asia Pacific

10.2.3.5.3.1. Market Estimation, 2013 – 2018

10.2.3.5.3.2. Market Forecast, 2019 – 2027

10.2.3.5.4. Middle East and Africa

10.2.3.5.4.1. Market Estimation, 2013 – 2018

10.2.3.5.4.2. Market Forecast, 2019 – 2027

10.2.3.5.5. Latin America

10.2.3.5.5.1. Market Estimation, 2013 – 2018

10.2.3.5.5.2. Market Forecast, 2019 – 2027

10.2.4. Thin Layer Chromatography

10.2.4.1. Definition

10.2.4.2. Market Estimation and Penetration, 2013 – 2018

10.2.4.3. Market Forecast, 2019 – 2027

10.2.4.4. Compound Annual Growth Rate (CAGR)

10.2.4.5. Regional Bifurcation

10.2.4.5.1. North America

10.2.4.5.1.1. Market Estimation, 2013 – 2018

10.2.4.5.1.2. Market Forecast, 2019 – 2027

10.2.4.5.2. Europe

10.2.4.5.2.1. Market Estimation, 2013 – 2018

10.2.4.5.2.2. Market Forecast, 2019 – 2027

10.2.4.5.3. Asia Pacific

10.2.4.5.3.1. Market Estimation, 2013 – 2018

10.2.4.5.3.2. Market Forecast, 2019 – 2027

10.2.4.5.4. Middle East and Africa

10.2.4.5.4.1. Market Estimation, 2013 – 2018

10.2.4.5.4.2. Market Forecast, 2019 – 2027

10.2.4.5.5. Latin America

10.2.4.5.5.1. Market Estimation, 2013 – 2018

10.2.4.5.5.2. Market Forecast, 2019 – 2027

10.2.5. Radio immuno assay

10.2.5.1. Definition

10.2.5.2. Market Estimation and Penetration, 2013 – 2018

10.2.5.3. Market Forecast, 2019 – 2027

10.2.5.4. Compound Annual Growth Rate (CAGR)

10.2.5.5. Regional Bifurcation

10.2.5.5.1. North America

10.2.5.5.1.1. Market Estimation, 2013 – 2018

10.2.5.5.1.2. Market Forecast, 2019 – 2027

10.2.5.5.2. Europe

10.2.5.5.2.1. Market Estimation, 2013 – 2018

10.2.5.5.2.2. Market Forecast, 2019 – 2027

10.2.5.5.3. Asia Pacific

10.2.5.5.3.1. Market Estimation, 2013 – 2018

10.2.5.5.3.2. Market Forecast, 2019 – 2027

10.2.5.5.4. Middle East and Africa

10.2.5.5.4.1. Market Estimation, 2013 – 2018

10.2.5.5.4.2. Market Forecast, 2019 – 2027

10.2.5.5.5. Latin America

10.2.5.5.5.1. Market Estimation, 2013 – 2018

10.2.5.5.5.2. Market Forecast, 2019 – 2027

10.2.6. Enzyme immune assay

10.2.6.1. Definition

10.2.6.2. Market Estimation and Penetration, 2013 – 2018

10.2.6.3. Market Forecast, 2019 – 2027

10.2.6.4. Compound Annual Growth Rate (CAGR)

10.2.6.5. Regional Bifurcation

10.2.6.5.1. North America

10.2.6.5.1.1. Market Estimation, 2013 – 2018

10.2.6.5.1.2. Market Forecast, 2019 – 2027

10.2.6.5.2. Europe

10.2.6.5.2.1. Market Estimation, 2013 – 2018

10.2.6.5.2.2. Market Forecast, 2019 – 2027

10.2.6.5.3. Asia Pacific

10.2.6.5.3.1. Market Estimation, 2013 – 2018

10.2.6.5.3.2. Market Forecast, 2019 – 2027

10.2.6.5.4. Middle East and Africa

10.2.6.5.4.1. Market Estimation, 2013 – 2018

10.2.6.5.4.2. Market Forecast, 2019 – 2027

10.2.6.5.5. Latin America

10.2.6.5.5.1. Market Estimation, 2013 – 2018

10.2.6.5.5.2. Market Forecast, 2019 – 2027

10.2.7. Spectrophotometry and Fluorimetry

10.2.7.1. Definition

10.2.7.2. Market Estimation and Penetration, 2013 – 2018

10.2.7.3. Market Forecast, 2019 – 2027

10.2.7.4. Compound Annual Growth Rate (CAGR)

10.2.7.5. Regional Bifurcation

10.2.7.5.1. North America

10.2.7.5.1.1. Market Estimation, 2013 – 2018

10.2.7.5.1.2. Market Forecast, 2019 – 2027

10.2.7.5.2. Europe

10.2.7.5.2.1. Market Estimation, 2013 – 2018

10.2.7.5.2.2. Market Forecast, 2019 – 2027

10.2.7.5.3. Asia Pacific

10.2.7.5.3.1. Market Estimation, 2013 – 2018

10.2.7.5.3.2. Market Forecast, 2019 – 2027

10.2.7.5.4. Middle East and Africa

10.2.7.5.4.1. Market Estimation, 2013 – 2018

10.2.7.5.4.2. Market Forecast, 2019 – 2027

10.2.7.5.5. Latin America

10.2.7.5.5.1. Market Estimation, 2013 – 2018

10.2.7.5.5.2. Market Forecast, 2019 – 2027

10.2.8. Others

10.2.8.1. Definition

10.2.8.2. Market Estimation and Penetration, 2013 – 2018

10.2.8.3. Market Forecast, 2019 – 2027

10.2.8.4. Compound Annual Growth Rate (CAGR)

10.2.8.5. Regional Bifurcation

10.2.8.5.1. North America

10.2.8.5.1.1. Market Estimation, 2013 – 2018

10.2.8.5.1.2. Market Forecast, 2019 – 2027

10.2.8.5.2. Europe

10.2.8.5.2.1. Market Estimation, 2013 – 2018

10.2.8.5.2.2. Market Forecast, 2019 – 2027

10.2.8.5.3. Asia Pacific

10.2.8.5.3.1. Market Estimation, 2013 – 2018

10.2.8.5.3.2. Market Forecast, 2019 – 2027

10.2.8.5.4. Middle East and Africa

10.2.8.5.4.1. Market Estimation, 2013 – 2018

10.2.8.5.4.2. Market Forecast, 2019 – 2027

10.2.8.5.5. Latin America

10.2.8.5.5.1. Market Estimation, 2013 – 2018

10.2.8.5.5.2. Market Forecast, 2019 – 2027

10.3. Key Segment for Channeling Investments

10.3.1. By Technology

11. Global Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 – 2027

11.1. Overview

11.2. Global Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

11.2.1. Hospitals and Clinics

11.2.1.1. Definition

11.2.1.2. Market Estimation and Penetration, 2013 – 2018

11.2.1.3. Market Forecast, 2019 – 2027

11.2.1.4. Compound Annual Growth Rate (CAGR)

11.2.1.5. Regional Bifurcation

11.2.1.5.1. North America

11.2.1.5.1.1. Market Estimation, 2013 – 2018

11.2.1.5.1.2. Market Forecast, 2019 – 2027

11.2.1.5.2. Europe

11.2.1.5.2.1. Market Estimation, 2013 – 2018

11.2.1.5.2.2. Market Forecast, 2019 – 2027

11.2.1.5.3. Asia Pacific

11.2.1.5.3.1. Market Estimation, 2013 – 2018

11.2.1.5.3.2. Market Forecast, 2019 – 2027

11.2.1.5.4. Middle East and Africa

11.2.1.5.4.1. Market Estimation, 2013 – 2018

11.2.1.5.4.2. Market Forecast, 2019 – 2027

11.2.1.5.5. Latin America

11.2.1.5.5.1. Market Estimation, 2013 – 2018

11.2.1.5.5.2. Market Forecast, 2019 – 2027

11.2.2. Diagnostic centers

11.2.2.1. Definition

11.2.2.2. Market Estimation and Penetration, 2013 – 2018

11.2.2.3. Market Forecast, 2019 – 2027

11.2.2.4. Compound Annual Growth Rate (CAGR)

11.2.2.5. Regional Bifurcation

11.2.2.5.1. North America

11.2.2.5.1.1. Market Estimation, 2013 – 2018

11.2.2.5.1.2. Market Forecast, 2019 – 2027

11.2.2.5.2. Europe

11.2.2.5.2.1. Market Estimation, 2013 – 2018

11.2.2.5.2.2. Market Forecast, 2019 – 2027

11.2.2.5.3. Asia Pacific

11.2.2.5.3.1. Market Estimation, 2013 – 2018

11.2.2.5.3.2. Market Forecast, 2019 – 2027

11.2.2.5.4. Middle East and Africa

11.2.2.5.4.1. Market Estimation, 2013 – 2018

11.2.2.5.4.2. Market Forecast, 2019 – 2027

11.2.2.5.5. Latin America

11.2.2.5.5.1. Market Estimation, 2013 – 2018

11.2.2.5.5.2. Market Forecast, 2019 – 2027

11.2.3. Research institutes

11.2.3.1. Definition

11.2.3.2. Market Estimation and Penetration, 2013 – 2018

11.2.3.3. Market Forecast, 2019 – 2027

11.2.3.4. Compound Annual Growth Rate (CAGR)

11.2.3.5. Regional Bifurcation

11.2.3.5.1. North America

11.2.3.5.1.1. Market Estimation, 2013 – 2018

11.2.3.5.1.2. Market Forecast, 2019 – 2027

11.2.3.5.2. Europe

11.2.3.5.2.1. Market Estimation, 2013 – 2018

11.2.3.5.2.2. Market Forecast, 2019 – 2027

11.2.3.5.3. Asia Pacific

11.2.3.5.3.1. Market Estimation, 2013 – 2018

11.2.3.5.3.2. Market Forecast, 2019 – 2027

11.2.3.5.4. Middle East and Africa

11.2.3.5.4.1. Market Estimation, 2013 – 2018

11.2.3.5.4.2. Market Forecast, 2019 – 2027

11.2.3.5.5. Latin America

11.2.3.5.5.1. Market Estimation, 2013 – 2018

11.2.3.5.5.2. Market Forecast, 2019 – 2027

11.2.4. Others

11.2.4.1. Definition

11.2.4.2. Market Estimation and Penetration, 2013 – 2018

11.2.4.3. Market Forecast, 2019 – 2027

11.2.4.4. Compound Annual Growth Rate (CAGR)

11.2.4.5. Regional Bifurcation

11.2.4.5.1. North America

11.2.4.5.1.1. Market Estimation, 2013 – 2018

11.2.4.5.1.2. Market Forecast, 2019 – 2027

11.2.4.5.2. Europe

11.2.4.5.2.1. Market Estimation, 2013 – 2018

11.2.4.5.2.2. Market Forecast, 2019 – 2027

11.2.4.5.3. Asia Pacific

11.2.4.5.3.1. Market Estimation, 2013 – 2018

11.2.4.5.3.2. Market Forecast, 2019 – 2027

11.2.4.5.4. Middle East and Africa

11.2.4.5.4.1. Market Estimation, 2013 – 2018

11.2.4.5.4.2. Market Forecast, 2019 – 2027

11.2.4.5.5. Latin America

11.2.4.5.5.1. Market Estimation, 2013 – 2018

11.2.4.5.5.2. Market Forecast, 2019 – 2027

11.3. Key Segment for Channeling Investments

11.3.1. By End Users

12. North America Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 - 2027

12.1. Overview

12.1.1. North America Therapeutic Drug Monitoring Market Revenue (US$ Mn)

12.2. North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

12.2.1. Antibiotics

12.2.2. Cardiac Drugs

12.2.3. Antiepileptics

12.2.4. Bronchodilators

12.2.5. Immunosuppressants

12.2.6. Anti-cancer drugs

12.2.7. Psychiatric drugs

12.2.8. Antiarrythmics

12.2.9. Others

12.3. North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

12.3.1. Consumables

12.3.2. Equipment

12.3.2.1. Immunoassay Analyzers

12.3.2.2. Chromatography and MS Detectors

12.3.2.3. Others

12.3.3. Others

12.4. North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

12.4.1. Fluorescence Immunoassay

12.4.2. Chemiluminescent Immunoassays

12.4.3. Radioimmunassay

12.4.4. Thin Layer Chromatography

12.4.5. Radio immuno assay

12.4.6. Enzyme immune assay

12.4.7. Spectrophotometry and Fluorimetry

12.4.8. Others

12.5. North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

12.5.1. Hospitals and Clinics

12.5.2. Diagnostic centers

12.5.3. Research institutes

12.5.4. Others

12.6. North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country

12.6.1. U.S

12.6.1.1. U.S Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

12.6.1.1.1. Antibiotics

12.6.1.1.2. Cardiac Drugs

12.6.1.1.3. Antiepileptics

12.6.1.1.4. Bronchodilators

12.6.1.1.5. Immunosuppressants

12.6.1.1.6. Anti-cancer drugs

12.6.1.1.7. Psychiatric drugs

12.6.1.1.8. Antiarrythmics

12.6.1.1.9. Others

12.6.1.2. U.S Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

12.6.1.2.1. Consumables

12.6.1.2.2. Equipment

12.6.1.2.2.1. Immunoassay Analyzers

12.6.1.2.2.2. Chromatography and MS Detectors

12.6.1.2.2.3. Others

12.6.1.2.3. Others

12.6.1.3. U.S Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

12.6.1.3.1. Fluorescence Immunoassay

12.6.1.3.2. Chemiluminescent Immunoassays

12.6.1.3.3. Radioimmunassay

12.6.1.3.4. Thin Layer Chromatography

12.6.1.3.5. Radio immuno assay

12.6.1.3.6. Enzyme immune assay

12.6.1.3.7. Spectrophotometry and Fluorimetry

12.6.1.3.8. Others

12.6.1.4. U.S Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

12.6.1.4.1. Hospitals and Clinics

12.6.1.4.2. Diagnostic centers

12.6.1.4.3. Research institutes

12.6.1.4.4. Others

12.6.2. Canada

12.6.2.1. Canada Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

12.6.2.1.1. Antibiotics

12.6.2.1.2. Cardiac Drugs

12.6.2.1.3. Antiepileptics

12.6.2.1.4. Bronchodilators

12.6.2.1.5. Immunosuppressants

12.6.2.1.6. Anti-cancer drugs

12.6.2.1.7. Psychiatric drugs

12.6.2.1.8. Antiarrythmics

12.6.2.1.9. Others

12.6.2.2. Canada Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

12.6.2.2.1. Consumables

12.6.2.2.2. Equipment

12.6.2.2.2.1. Immunoassay Analyzers

12.6.2.2.2.2. Chromatography and MS Detectors

12.6.2.2.2.3. Others

12.6.2.2.3. Others

12.6.2.3. Canada Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

12.6.2.3.1. Fluorescence Immunoassay

12.6.2.3.2. Chemiluminescent Immunoassays

12.6.2.3.3. Radioimmunassay

12.6.2.3.4. Thin Layer Chromatography

12.6.2.3.5. Radio immuno assay

12.6.2.3.6. Enzyme immune assay

12.6.2.3.7. Spectrophotometry and Fluorimetry

12.6.2.3.8. Others

12.6.2.4. Canada Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

12.6.2.4.1. Hospitals and Clinics

12.6.2.4.2. Diagnostic centers

12.6.2.4.3. Research institutes

12.6.2.4.4. Others

12.6.3. Mexico

12.6.3.1. Mexico Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

12.6.3.1.1. Antibiotics

12.6.3.1.2. Cardiac Drugs

12.6.3.1.3. Antiepileptics

12.6.3.1.4. Bronchodilators

12.6.3.1.5. Immunosuppressants

12.6.3.1.6. Anti-cancer drugs

12.6.3.1.7. Psychiatric drugs

12.6.3.1.8. Antiarrythmics

12.6.3.1.9. Others

12.6.3.2. Mexico Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

12.6.3.2.1. Consumables

12.6.3.2.2. Equipment

12.6.3.2.2.1. Immunoassay Analyzers

12.6.3.2.2.2. Chromatography and MS Detectors

12.6.3.2.2.3. Others

12.6.3.2.3. Others

12.6.3.3. Mexico Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

12.6.3.3.1. Fluorescence Immunoassay

12.6.3.3.2. Chemiluminescent Immunoassays

12.6.3.3.3. Radioimmunassay

12.6.3.3.4. Thin Layer Chromatography

12.6.3.3.5. Radio immuno assay

12.6.3.3.6. Enzyme immune assay

12.6.3.3.7. Spectrophotometry and Fluorimetry

12.6.3.3.8. Others

12.6.3.4. Mexico Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

12.6.3.4.1. Hospitals and Clinics

12.6.3.4.2. Diagnostic centers

12.6.3.4.3. Research institutes

12.6.3.4.4. Others

12.6.4. Rest of North America

12.6.4.1. Rest of North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

12.6.4.1.1. Antibiotics

12.6.4.1.2. Cardiac Drugs

12.6.4.1.3. Antiepileptics

12.6.4.1.4. Bronchodilators

12.6.4.1.5. Immunosuppressants

12.6.4.1.6. Anti-cancer drugs

12.6.4.1.7. Psychiatric drugs

12.6.4.1.8. Antiarrythmics

12.6.4.1.9. Others

12.6.4.2. Rest of North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

12.6.4.2.1. Consumables

12.6.4.2.2. Equipment

12.6.4.2.2.1. Immunoassay Analyzers

12.6.4.2.2.2. Chromatography and MS Detectors

12.6.4.2.2.3. Others

12.6.4.2.3. Others

12.6.4.3. Rest of North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

12.6.4.3.1. Fluorescence Immunoassay

12.6.4.3.2. Chemiluminescent Immunoassays

12.6.4.3.3. Radioimmunassay

12.6.4.3.4. Thin Layer Chromatography

12.6.4.3.5. Radio immuno assay

12.6.4.3.6. Enzyme immune assay

12.6.4.3.7. Spectrophotometry and Fluorimetry

12.6.4.3.8. Others

12.6.4.4. Rest of North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

12.6.4.4.1. Hospitals and Clinics

12.6.4.4.2. Diagnostic centers

12.6.4.4.3. Research institutes

12.6.4.4.4. Others

12.7. Key Segment for Channeling Investments

12.7.1. By Country

12.7.2. By Drugs

12.7.3. By Products

12.7.4. By Technology

12.7.5. By End Users

13. Europe Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 - 2027

13.1. Overview

13.1.1. Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn)

13.2. Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

13.2.1. Antibiotics

13.2.2. Cardiac Drugs

13.2.3. Antiepileptics

13.2.4. Bronchodilators

13.2.5. Immunosuppressants

13.2.6. Anti-cancer drugs

13.2.7. Psychiatric drugs

13.2.8. Antiarrythmics

13.2.9. Others

13.3. Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

13.3.1. Consumables

13.3.2. Equipment

13.3.2.1. Immunoassay Analyzers

13.3.2.2. Chromatography and MS Detectors

13.3.2.3. Others

13.3.3. Others

13.4. Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

13.4.1. Fluorescence Immunoassay

13.4.2. Chemiluminescent Immunoassays

13.4.3. Radioimmunassay

13.4.4. Thin Layer Chromatography

13.4.5. Radio immuno assay

13.4.6. Enzyme immune assay

13.4.7. Spectrophotometry and Fluorimetry

13.4.8. Others

13.5. Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

13.5.1. Hospitals and Clinics

13.5.2. Diagnostic centers

13.5.3. Research institutes

13.5.4. Others

13.6. Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country

13.6.1. France

13.6.1.1. France Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

13.6.1.1.1. Antibiotics

13.6.1.1.2. Cardiac Drugs

13.6.1.1.3. Antiepileptics

13.6.1.1.4. Bronchodilators

13.6.1.1.5. Immunosuppressants

13.6.1.1.6. Anti-cancer drugs

13.6.1.1.7. Psychiatric drugs

13.6.1.1.8. Antiarrythmics

13.6.1.1.9. Others

13.6.1.2. France Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

13.6.1.2.1. Consumables

13.6.1.2.2. Equipment

13.6.1.2.2.1. Immunoassay Analyzers

13.6.1.2.2.2. Chromatography and MS Detectors

13.6.1.2.2.3. Others

13.6.1.2.3. Others

13.6.1.3. France Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

13.6.1.3.1. Fluorescence Immunoassay

13.6.1.3.2. Chemiluminescent Immunoassays

13.6.1.3.3. Radioimmunassay

13.6.1.3.4. Thin Layer Chromatography

13.6.1.3.5. Radio immuno assay

13.6.1.3.6. Enzyme immune assay

13.6.1.3.7. Spectrophotometry and Fluorimetry

13.6.1.3.8. Others

13.6.1.4. France Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

13.6.1.4.1. Hospitals and Clinics

13.6.1.4.2. Diagnostic centers

13.6.1.4.3. Research institutes

13.6.1.4.4. Others

13.6.2. The UK

13.6.2.1. The UK Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

13.6.2.1.1. Antibiotics

13.6.2.1.2. Cardiac Drugs

13.6.2.1.3. Antiepileptics

13.6.2.1.4. Bronchodilators

13.6.2.1.5. Immunosuppressants

13.6.2.1.6. Anti-cancer drugs

13.6.2.1.7. Psychiatric drugs

13.6.2.1.8. Antiarrythmics

13.6.2.1.9. Others

13.6.2.2. The UK Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

13.6.2.2.1. Consumables

13.6.2.2.2. Equipment

13.6.2.2.2.1. Immunoassay Analyzers

13.6.2.2.2.2. Chromatography and MS Detectors

13.6.2.2.2.3. Others

13.6.2.2.3. Others

13.6.2.3. The UK Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

13.6.2.3.1. Fluorescence Immunoassay

13.6.2.3.2. Chemiluminescent Immunoassays

13.6.2.3.3. Radioimmunassay

13.6.2.3.4. Thin Layer Chromatography

13.6.2.3.5. Radio immuno assay

13.6.2.3.6. Enzyme immune assay

13.6.2.3.7. Spectrophotometry and Fluorimetry

13.6.2.3.8. Others

13.6.2.4. The UK Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

13.6.2.4.1. Hospitals and Clinics

13.6.2.4.2. Diagnostic centers

13.6.2.4.3. Research institutes

13.6.2.4.4. Others

13.6.3. Spain

13.6.3.1. Spain Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

13.6.3.1.1. Antibiotics

13.6.3.1.2. Cardiac Drugs

13.6.3.1.3. Antiepileptics

13.6.3.1.4. Bronchodilators

13.6.3.1.5. Immunosuppressants

13.6.3.1.6. Anti-cancer drugs

13.6.3.1.7. Psychiatric drugs

13.6.3.1.8. Antiarrythmics

13.6.3.1.9. Others

13.6.3.2. Spain Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

13.6.3.2.1. Consumables

13.6.3.2.2. Equipment

13.6.3.2.2.1. Immunoassay Analyzers

13.6.3.2.2.2. Chromatography and MS Detectors

13.6.3.2.2.3. Others

13.6.3.2.3. Others

13.6.3.3. Spain Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

13.6.3.3.1. Fluorescence Immunoassay

13.6.3.3.2. Chemiluminescent Immunoassays

13.6.3.3.3. Radioimmunassay

13.6.3.3.4. Thin Layer Chromatography

13.6.3.3.5. Radio immuno assay

13.6.3.3.6. Enzyme immune assay

13.6.3.3.7. Spectrophotometry and Fluorimetry

13.6.3.3.8. Others

13.6.3.4. Spain Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

13.6.3.4.1. Hospitals and Clinics

13.6.3.4.2. Diagnostic centers

13.6.3.4.3. Research institutes

13.6.3.4.4. Others

13.6.4. Germany

13.6.4.1. Germany Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

13.6.4.1.1. Antibiotics

13.6.4.1.2. Cardiac Drugs

13.6.4.1.3. Antiepileptics

13.6.4.1.4. Bronchodilators

13.6.4.1.5. Immunosuppressants

13.6.4.1.6. Anti-cancer drugs

13.6.4.1.7. Psychiatric drugs

13.6.4.1.8. Antiarrythmics

13.6.4.1.9. Others

13.6.4.2. Germany Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

13.6.4.2.1. Consumables

13.6.4.2.2. Equipment

13.6.4.2.2.1. Immunoassay Analyzers

13.6.4.2.2.2. Chromatography and MS Detectors

13.6.4.2.2.3. Others

13.6.4.2.3. Others

13.6.4.3. Germany Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

13.6.4.3.1. Fluorescence Immunoassay

13.6.4.3.2. Chemiluminescent Immunoassays

13.6.4.3.3. Radioimmunassay

13.6.4.3.4. Thin Layer Chromatography

13.6.4.3.5. Radio immuno assay

13.6.4.3.6. Enzyme immune assay

13.6.4.3.7. Spectrophotometry and Fluorimetry

13.6.4.3.8. Others

13.6.4.4. Germany Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

13.6.4.4.1. Hospitals and Clinics

13.6.4.4.2. Diagnostic centers

13.6.4.4.3. Research institutes

13.6.4.4.4. Others

13.6.5. Italy

13.6.5.1. Italy Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

13.6.5.1.1. Antibiotics

13.6.5.1.2. Cardiac Drugs

13.6.5.1.3. Antiepileptics

13.6.5.1.4. Bronchodilators

13.6.5.1.5. Immunosuppressants

13.6.5.1.6. Anti-cancer drugs

13.6.5.1.7. Psychiatric drugs

13.6.5.1.8. Antiarrythmics

13.6.5.1.9. Others

13.6.5.2. Italy Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

13.6.5.2.1. Consumables

13.6.5.2.2. Equipment

13.6.5.2.2.1. Immunoassay Analyzers

13.6.5.2.2.2. Chromatography and MS Detectors

13.6.5.2.2.3. Others

13.6.5.2.3. Others

13.6.5.3. Italy Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

13.6.5.3.1. Fluorescence Immunoassay

13.6.5.3.2. Chemiluminescent Immunoassays

13.6.5.3.3. Radioimmunassay

13.6.5.3.4. Thin Layer Chromatography

13.6.5.3.5. Radio immuno assay

13.6.5.3.6. Enzyme immune assay

13.6.5.3.7. Spectrophotometry and Fluorimetry

13.6.5.3.8. Others

13.6.5.4. Italy Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

13.6.5.4.1. Hospitals and Clinics

13.6.5.4.2. Diagnostic centers

13.6.5.4.3. Research institutes

13.6.5.4.4. Others

13.6.6. Nordic Countries

13.6.6.1. Nordic Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

13.6.6.1.1. Antibiotics

13.6.6.1.2. Cardiac Drugs

13.6.6.1.3. Antiepileptics

13.6.6.1.4. Bronchodilators

13.6.6.1.5. Immunosuppressants

13.6.6.1.6. Anti-cancer drugs

13.6.6.1.7. Psychiatric drugs

13.6.6.1.8. Antiarrythmics

13.6.6.1.9. Others

13.6.6.2. Nordic Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

13.6.6.2.1. Consumables

13.6.6.2.2. Equipment

13.6.6.2.2.1. Immunoassay Analyzers

13.6.6.2.2.2. Chromatography and MS Detectors

13.6.6.2.2.3. Others

13.6.6.2.3. Others

13.6.6.3. Nordic Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

13.6.6.3.1. Fluorescence Immunoassay

13.6.6.3.2. Chemiluminescent Immunoassays

13.6.6.3.3. Radioimmunassay

13.6.6.3.4. Thin Layer Chromatography

13.6.6.3.5. Radio immuno assay

13.6.6.3.6. Enzyme immune assay

13.6.6.3.7. Spectrophotometry and Fluorimetry

13.6.6.3.8. Others

13.6.6.4. Nordic Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

13.6.6.4.1. Hospitals and Clinics

13.6.6.4.2. Diagnostic centers

13.6.6.4.3. Research institutes

13.6.6.4.4. Others

13.6.6.5. Nordic Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country

13.6.6.5.1. Denmark

13.6.6.5.2. Finland

13.6.6.5.3. Iceland

13.6.6.5.4. Sweden

13.6.6.5.5. Norway

13.6.7. Benelux Union

13.6.7.1. Benelux Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

13.6.7.1.1. Antibiotics

13.6.7.1.2. Cardiac Drugs

13.6.7.1.3. Antiepileptics

13.6.7.1.4. Bronchodilators

13.6.7.1.5. Immunosuppressants

13.6.7.1.6. Anti-cancer drugs

13.6.7.1.7. Psychiatric drugs

13.6.7.1.8. Antiarrythmics

13.6.7.1.9. Others

13.6.7.2. Benelux Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

13.6.7.2.1. Consumables

13.6.7.2.2. Equipment

13.6.7.2.2.1. Immunoassay Analyzers

13.6.7.2.2.2. Chromatography and MS Detectors

13.6.7.2.2.3. Others

13.6.7.2.3. Others

13.6.7.3. Benelux Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

13.6.7.3.1. Fluorescence Immunoassay

13.6.7.3.2. Chemiluminescent Immunoassays

13.6.7.3.3. Radioimmunassay

13.6.7.3.4. Thin Layer Chromatography

13.6.7.3.5. Radio immuno assay

13.6.7.3.6. Enzyme immune assay

13.6.7.3.7. Spectrophotometry and Fluorimetry

13.6.7.3.8. Others

13.6.7.4. Benelux Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

13.6.7.4.1. Hospitals and Clinics

13.6.7.4.2. Diagnostic centers

13.6.7.4.3. Research institutes

13.6.7.4.4. Others

13.6.7.5. Benelux Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country

13.6.7.5.1. Belgium

13.6.7.5.2. The Netherlands

13.6.7.5.3. Luxembourg

13.6.8. Rest of Europe

13.6.8.1. Rest of Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

13.6.8.1.1. Antibiotics

13.6.8.1.2. Cardiac Drugs

13.6.8.1.3. Antiepileptics

13.6.8.1.4. Bronchodilators

13.6.8.1.5. Immunosuppressants

13.6.8.1.6. Anti-cancer drugs

13.6.8.1.7. Psychiatric drugs

13.6.8.1.8. Antiarrythmics

13.6.8.1.9. Others

13.6.8.2. Rest of Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

13.6.8.2.1. Consumables

13.6.8.2.2. Equipment

13.6.8.2.2.1. Immunoassay Analyzers

13.6.8.2.2.2. Chromatography and MS Detectors

13.6.8.2.2.3. Others

13.6.8.2.3. Others

13.6.8.3. Rest of Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

13.6.8.3.1. Fluorescence Immunoassay

13.6.8.3.2. Chemiluminescent Immunoassays

13.6.8.3.3. Radioimmunassay

13.6.8.3.4. Thin Layer Chromatography

13.6.8.3.5. Radio immuno assay

13.6.8.3.6. Enzyme immune assay

13.6.8.3.7. Spectrophotometry and Fluorimetry

13.6.8.3.8. Others

13.6.8.4. Rest of Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

13.6.8.4.1. Hospitals and Clinics

13.6.8.4.2. Diagnostic centers

13.6.8.4.3. Research institutes

13.6.8.4.4. Others

13.7. Key Segment for Channeling Investments

13.7.1. By Country

13.7.2. By Drugs

13.7.3. By Products

13.7.4. By Technology

13.7.5. By End Users

14. Asia Pacific Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 - 2027

14.1. Overview

14.1.1. Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn)

14.2. Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

14.2.1. Antibiotics

14.2.2. Cardiac Drugs

14.2.3. Antiepileptics

14.2.4. Bronchodilators

14.2.5. Immunosuppressants

14.2.6. Anti-cancer drugs

14.2.7. Psychiatric drugs

14.2.8. Antiarrythmics

14.2.9. Others

14.3. Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

14.3.1. Consumables

14.3.2. Equipment

14.3.2.1. Immunoassay Analyzers

14.3.2.2. Chromatography and MS Detectors

14.3.2.3. Others

14.3.3. Others

14.4. Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

14.4.1. Fluorescence Immunoassay

14.4.2. Chemiluminescent Immunoassays

14.4.3. Radioimmunassay

14.4.4. Thin Layer Chromatography

14.4.5. Radio immuno assay

14.4.6. Enzyme immune assay

14.4.7. Spectrophotometry and Fluorimetry

14.4.8. Others

14.5. Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

14.5.1. Hospitals and Clinics

14.5.2. Diagnostic centers

14.5.3. Research institutes

14.5.4. Others

14.6. Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country

14.6.1. China

14.6.1.1. China Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

14.6.1.1.1. Antibiotics

14.6.1.1.2. Cardiac Drugs

14.6.1.1.3. Antiepileptics

14.6.1.1.4. Bronchodilators

14.6.1.1.5. Immunosuppressants

14.6.1.1.6. Anti-cancer drugs

14.6.1.1.7. Psychiatric drugs

14.6.1.1.8. Antiarrythmics

14.6.1.1.9. Others

14.6.1.2. China Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

14.6.1.2.1. Consumables

14.6.1.2.2. Equipment

14.6.1.2.2.1. Immunoassay Analyzers

14.6.1.2.2.2. Chromatography and MS Detectors

14.6.1.2.2.3. Others

14.6.1.2.3. Others

14.6.1.3. China Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

14.6.1.3.1. Fluorescence Immunoassay

14.6.1.3.2. Chemiluminescent Immunoassays

14.6.1.3.3. Radioimmunassay

14.6.1.3.4. Thin Layer Chromatography

14.6.1.3.5. Radio immuno assay

14.6.1.3.6. Enzyme immune assay

14.6.1.3.7. Spectrophotometry and Fluorimetry

14.6.1.3.8. Others

14.6.1.4. China Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

14.6.1.4.1. Hospitals and Clinics

14.6.1.4.2. Diagnostic centers

14.6.1.4.3. Research institutes

14.6.1.4.4. Others

14.6.2. Japan

14.6.2.1. Japan Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

14.6.2.1.1. Antibiotics

14.6.2.1.2. Cardiac Drugs

14.6.2.1.3. Antiepileptics

14.6.2.1.4. Bronchodilators

14.6.2.1.5. Immunosuppressants

14.6.2.1.6. Anti-cancer drugs

14.6.2.1.7. Psychiatric drugs

14.6.2.1.8. Antiarrythmics

14.6.2.1.9. Others

14.6.2.2. Japan Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

14.6.2.2.1. Consumables

14.6.2.2.2. Equipment

14.6.2.2.2.1. Immunoassay Analyzers

14.6.2.2.2.2. Chromatography and MS Detectors

14.6.2.2.2.3. Others

14.6.2.2.3. Others

14.6.2.3. Japan Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

14.6.2.3.1. Fluorescence Immunoassay

14.6.2.3.2. Chemiluminescent Immunoassays

14.6.2.3.3. Radioimmunassay

14.6.2.3.4. Thin Layer Chromatography

14.6.2.3.5. Radio immuno assay

14.6.2.3.6. Enzyme immune assay

14.6.2.3.7. Spectrophotometry and Fluorimetry

14.6.2.3.8. Others

14.6.2.4. Japan Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

14.6.2.4.1. Hospitals and Clinics

14.6.2.4.2. Diagnostic centers

14.6.2.4.3. Research institutes

14.6.2.4.4. Others

14.6.3. India

14.6.3.1. India Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

14.6.3.1.1. Antibiotics

14.6.3.1.2. Cardiac Drugs

14.6.3.1.3. Antiepileptics

14.6.3.1.4. Bronchodilators

14.6.3.1.5. Immunosuppressants

14.6.3.1.6. Anti-cancer drugs

14.6.3.1.7. Psychiatric drugs

14.6.3.1.8. Antiarrythmics

14.6.3.1.9. Others

14.6.3.2. India Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

14.6.3.2.1. Consumables

14.6.3.2.2. Equipment

14.6.3.2.2.1. Immunoassay Analyzers

14.6.3.2.2.2. Chromatography and MS Detectors

14.6.3.2.2.3. Others

14.6.3.2.3. Others

14.6.3.3. India Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

14.6.3.3.1. Fluorescence Immunoassay

14.6.3.3.2. Chemiluminescent Immunoassays

14.6.3.3.3. Radioimmunassay

14.6.3.3.4. Thin Layer Chromatography

14.6.3.3.5. Radio immuno assay

14.6.3.3.6. Enzyme immune assay

14.6.3.3.7. Spectrophotometry and Fluorimetry

14.6.3.3.8. Others

14.6.3.4. India Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

14.6.3.4.1. Hospitals and Clinics

14.6.3.4.2. Diagnostic centers

14.6.3.4.3. Research institutes

14.6.3.4.4. Others

14.6.4. New Zealand

14.6.4.1. New Zealand Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

14.6.4.1.1. Antibiotics

14.6.4.1.2. Cardiac Drugs

14.6.4.1.3. Antiepileptics

14.6.4.1.4. Bronchodilators

14.6.4.1.5. Immunosuppressants

14.6.4.1.6. Anti-cancer drugs

14.6.4.1.7. Psychiatric drugs

14.6.4.1.8. Antiarrythmics

14.6.4.1.9. Others

14.6.4.2. New Zealand Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

14.6.4.2.1. Consumables

14.6.4.2.2. Equipment

14.6.4.2.2.1. Immunoassay Analyzers

14.6.4.2.2.2. Chromatography and MS Detectors

14.6.4.2.2.3. Others

14.6.4.2.3. Others

14.6.4.3. New Zealand Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

14.6.4.3.1. Fluorescence Immunoassay

14.6.4.3.2. Chemiluminescent Immunoassays

14.6.4.3.3. Radioimmunassay

14.6.4.3.4. Thin Layer Chromatography

14.6.4.3.5. Radio immuno assay

14.6.4.3.6. Enzyme immune assay

14.6.4.3.7. Spectrophotometry and Fluorimetry

14.6.4.3.8. Others

14.6.4.4. New Zealand Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

14.6.4.4.1. Hospitals and Clinics

14.6.4.4.2. Diagnostic centers

14.6.4.4.3. Research institutes

14.6.4.4.4. Others

14.6.5. Australia

14.6.5.1. Australia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

14.6.5.1.1. Antibiotics

14.6.5.1.2. Cardiac Drugs

14.6.5.1.3. Antiepileptics

14.6.5.1.4. Bronchodilators

14.6.5.1.5. Immunosuppressants

14.6.5.1.6. Anti-cancer drugs

14.6.5.1.7. Psychiatric drugs

14.6.5.1.8. Antiarrythmics

14.6.5.1.9. Others

14.6.5.2. Australia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

14.6.5.2.1. Consumables

14.6.5.2.2. Equipment

14.6.5.2.2.1. Immunoassay Analyzers

14.6.5.2.2.2. Chromatography and MS Detectors

14.6.5.2.2.3. Others

14.6.5.2.3. Others

14.6.5.3. Australia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

14.6.5.3.1. Fluorescence Immunoassay

14.6.5.3.2. Chemiluminescent Immunoassays

14.6.5.3.3. Radioimmunassay

14.6.5.3.4. Thin Layer Chromatography

14.6.5.3.5. Radio immuno assay

14.6.5.3.6. Enzyme immune assay

14.6.5.3.7. Spectrophotometry and Fluorimetry

14.6.5.3.8. Others

14.6.5.4. Australia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

14.6.5.4.1. Hospitals and Clinics

14.6.5.4.2. Diagnostic centers

14.6.5.4.3. Research institutes

14.6.5.4.4. Others

14.6.6. South Korea

14.6.6.1. South Korea Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

14.6.6.1.1. Antibiotics

14.6.6.1.2. Cardiac Drugs

14.6.6.1.3. Antiepileptics

14.6.6.1.4. Bronchodilators

14.6.6.1.5. Immunosuppressants

14.6.6.1.6. Anti-cancer drugs

14.6.6.1.7. Psychiatric drugs

14.6.6.1.8. Antiarrythmics

14.6.6.1.9. Others

14.6.6.2. South Korea Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

14.6.6.2.1. Consumables

14.6.6.2.2. Equipment

14.6.6.2.2.1. Immunoassay Analyzers

14.6.6.2.2.2. Chromatography and MS Detectors

14.6.6.2.2.3. Others

14.6.6.2.3. Others

14.6.6.3. South Korea Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

14.6.6.3.1. Fluorescence Immunoassay

14.6.6.3.2. Chemiluminescent Immunoassays

14.6.6.3.3. Radioimmunassay

14.6.6.3.4. Thin Layer Chromatography

14.6.6.3.5. Radio immuno assay

14.6.6.3.6. Enzyme immune assay

14.6.6.3.7. Spectrophotometry and Fluorimetry

14.6.6.3.8. Others

14.6.6.4. South Korea Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

14.6.6.4.1. Hospitals and Clinics

14.6.6.4.2. Diagnostic centers

14.6.6.4.3. Research institutes

14.6.6.4.4. Others

14.6.7. Southeast Asia

14.6.7.1. Southeast Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

14.6.7.1.1. Antibiotics

14.6.7.1.2. Cardiac Drugs

14.6.7.1.3. Antiepileptics

14.6.7.1.4. Bronchodilators

14.6.7.1.5. Immunosuppressants

14.6.7.1.6. Anti-cancer drugs

14.6.7.1.7. Psychiatric drugs

14.6.7.1.8. Antiarrythmics

14.6.7.1.9. Others

14.6.7.2. Southeast Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

14.6.7.2.1. Consumables

14.6.7.2.2. Equipment

14.6.7.2.2.1. Immunoassay Analyzers

14.6.7.2.2.2. Chromatography and MS Detectors

14.6.7.2.2.3. Others

14.6.7.2.3. Others

14.6.7.3. Southeast Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

14.6.7.3.1. Fluorescence Immunoassay

14.6.7.3.2. Chemiluminescent Immunoassays

14.6.7.3.3. Radioimmunassay

14.6.7.3.4. Thin Layer Chromatography

14.6.7.3.5. Radio immuno assay

14.6.7.3.6. Enzyme immune assay

14.6.7.3.7. Spectrophotometry and Fluorimetry

14.6.7.3.8. Others

14.6.7.4. Southeast Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

14.6.7.4.1. Hospitals and Clinics

14.6.7.4.2. Diagnostic centers

14.6.7.4.3. Research institutes

14.6.7.4.4. Others

14.6.7.5. Southeast Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country

14.6.7.5.1. Indonesia

14.6.7.5.2. Thailand

14.6.7.5.3. Malaysia

14.6.7.5.4. Singapore

14.6.7.5.5. Rest of Southeast Asia

14.6.8. Rest of Asia Pacific

14.6.8.1. Rest of Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

14.6.8.1.1. Antibiotics

14.6.8.1.2. Cardiac Drugs

14.6.8.1.3. Antiepileptics

14.6.8.1.4. Bronchodilators

14.6.8.1.5. Immunosuppressants

14.6.8.1.6. Anti-cancer drugs

14.6.8.1.7. Psychiatric drugs

14.6.8.1.8. Antiarrythmics

14.6.8.1.9. Others

14.6.8.2. Rest of Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

14.6.8.2.1. Consumables

14.6.8.2.2. Equipment

14.6.8.2.2.1. Immunoassay Analyzers

14.6.8.2.2.2. Chromatography and MS Detectors

14.6.8.2.2.3. Others

14.6.8.2.3. Others

14.6.8.3. Rest of Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

14.6.8.3.1. Fluorescence Immunoassay

14.6.8.3.2. Chemiluminescent Immunoassays

14.6.8.3.3. Radioimmunassay

14.6.8.3.4. Thin Layer Chromatography

14.6.8.3.5. Radio immuno assay

14.6.8.3.6. Enzyme immune assay

14.6.8.3.7. Spectrophotometry and Fluorimetry

14.6.8.3.8. Others

14.6.8.4. Rest of Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

14.6.8.4.1. Hospitals and Clinics

14.6.8.4.2. Diagnostic centers

14.6.8.4.3. Research institutes

14.6.8.4.4. Others

14.7. Key Segment for Channeling Investments

14.7.1. By Country

14.7.2. By Drugs

14.7.3. By Products

14.7.4. By Technology

14.7.5. By End Users

15. Middle East and Africa Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 - 2027

15.1. Overview

15.1.1. Middle East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn)

15.2. Middle East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

15.2.1. Antibiotics

15.2.2. Cardiac Drugs

15.2.3. Antiepileptics

15.2.4. Bronchodilators

15.2.5. Immunosuppressants

15.2.6. Anti-cancer drugs

15.2.7. Psychiatric drugs

15.2.8. Antiarrythmics

15.2.9. Others

15.3. Middle East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

15.3.1. Consumables

15.3.2. Equipment

15.3.2.1. Immunoassay Analyzers

15.3.2.2. Chromatography and MS Detectors

15.3.2.3. Others

15.3.3. Others

15.4. Middle East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

15.4.1. Fluorescence Immunoassay

15.4.2. Chemiluminescent Immunoassays

15.4.3. Radioimmunassay

15.4.4. Thin Layer Chromatography

15.4.5. Radio immuno assay

15.4.6. Enzyme immune assay

15.4.7. Spectrophotometry and Fluorimetry

15.4.8. Others

15.5. Middle East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

15.5.1. Hospitals and Clinics

15.5.2. Diagnostic centers

15.5.3. Research institutes

15.5.4. Others

15.6. Middle East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country

15.6.1. Saudi Arabia

15.6.1.1. Saudi Arabia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

15.6.1.1.1. Antibiotics

15.6.1.1.2. Cardiac Drugs

15.6.1.1.3. Antiepileptics

15.6.1.1.4. Bronchodilators

15.6.1.1.5. Immunosuppressants

15.6.1.1.6. Anti-cancer drugs

15.6.1.1.7. Psychiatric drugs

15.6.1.1.8. Antiarrythmics

15.6.1.1.9. Others

15.6.1.2. Saudi Arabia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

15.6.1.2.1. Consumables

15.6.1.2.2. Equipment

15.6.1.2.2.1. Immunoassay Analyzers

15.6.1.2.2.2. Chromatography and MS Detectors

15.6.1.2.2.3. Others

15.6.1.2.3. Others

15.6.1.3. Saudi Arabia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

15.6.1.3.1. Fluorescence Immunoassay

15.6.1.3.2. Chemiluminescent Immunoassays

15.6.1.3.3. Radioimmunassay

15.6.1.3.4. Thin Layer Chromatography

15.6.1.3.5. Radio immuno assay

15.6.1.3.6. Enzyme immune assay

15.6.1.3.7. Spectrophotometry and Fluorimetry

15.6.1.3.8. Others

15.6.1.4. Saudi Arabia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

15.6.1.4.1. Hospitals and Clinics

15.6.1.4.2. Diagnostic centers

15.6.1.4.3. Research institutes

15.6.1.4.4. Others

15.6.2. UAE

15.6.2.1. UAE Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

15.6.2.1.1. Antibiotics

15.6.2.1.2. Cardiac Drugs

15.6.2.1.3. Antiepileptics

15.6.2.1.4. Bronchodilators

15.6.2.1.5. Immunosuppressants

15.6.2.1.6. Anti-cancer drugs

15.6.2.1.7. Psychiatric drugs

15.6.2.1.8. Antiarrythmics

15.6.2.1.9. Others

15.6.2.2. UAE Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

15.6.2.2.1. Consumables

15.6.2.2.2. Equipment

15.6.2.2.2.1. Immunoassay Analyzers

15.6.2.2.2.2. Chromatography and MS Detectors

15.6.2.2.2.3. Others

15.6.2.2.3. Others

15.6.2.3. UAE Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

15.6.2.3.1. Fluorescence Immunoassay

15.6.2.3.2. Chemiluminescent Immunoassays

15.6.2.3.3. Radioimmunassay

15.6.2.3.4. Thin Layer Chromatography

15.6.2.3.5. Radio immuno assay

15.6.2.3.6. Enzyme immune assay

15.6.2.3.7. Spectrophotometry and Fluorimetry

15.6.2.3.8. Others

15.6.2.4. UAE Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

15.6.2.4.1. Hospitals and Clinics

15.6.2.4.2. Diagnostic centers

15.6.2.4.3. Research institutes

15.6.2.4.4. Others

15.6.3. Egypt

15.6.3.1. Egypt Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

15.6.3.1.1. Antibiotics

15.6.3.1.2. Cardiac Drugs

15.6.3.1.3. Antiepileptics

15.6.3.1.4. Bronchodilators

15.6.3.1.5. Immunosuppressants

15.6.3.1.6. Anti-cancer drugs

15.6.3.1.7. Psychiatric drugs

15.6.3.1.8. Antiarrythmics

15.6.3.1.9. Others

15.6.3.2. Egypt Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

15.6.3.2.1. Consumables

15.6.3.2.2. Equipment

15.6.3.2.2.1. Immunoassay Analyzers

15.6.3.2.2.2. Chromatography and MS Detectors

15.6.3.2.2.3. Others

15.6.3.2.3. Others

15.6.3.3. Egypt Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

15.6.3.3.1. Fluorescence Immunoassay

15.6.3.3.2. Chemiluminescent Immunoassays

15.6.3.3.3. Radioimmunassay

15.6.3.3.4. Thin Layer Chromatography

15.6.3.3.5. Radio immuno assay

15.6.3.3.6. Enzyme immune assay

15.6.3.3.7. Spectrophotometry and Fluorimetry

15.6.3.3.8. Others

15.6.3.4. Egypt Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

15.6.3.4.1. Hospitals and Clinics

15.6.3.4.2. Diagnostic centers

15.6.3.4.3. Research institutes

15.6.3.4.4. Others

15.6.4. Kuwait

15.6.4.1. Kuwait Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

15.6.4.1.1. Antibiotics

15.6.4.1.2. Cardiac Drugs

15.6.4.1.3. Antiepileptics

15.6.4.1.4. Bronchodilators

15.6.4.1.5. Immunosuppressants

15.6.4.1.6. Anti-cancer drugs

15.6.4.1.7. Psychiatric drugs

15.6.4.1.8. Antiarrythmics

15.6.4.1.9. Others

15.6.4.2. Kuwait Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

15.6.4.2.1. Consumables

15.6.4.2.2. Equipment

15.6.4.2.2.1. Immunoassay Analyzers

15.6.4.2.2.2. Chromatography and MS Detectors

15.6.4.2.2.3. Others

15.6.4.2.3. Others

15.6.4.3. Kuwait Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

15.6.4.3.1. Fluorescence Immunoassay

15.6.4.3.2. Chemiluminescent Immunoassays

15.6.4.3.3. Radioimmunassay

15.6.4.3.4. Thin Layer Chromatography

15.6.4.3.5. Radio immuno assay

15.6.4.3.6. Enzyme immune assay

15.6.4.3.7. Spectrophotometry and Fluorimetry

15.6.4.3.8. Others

15.6.4.4. Kuwait Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

15.6.4.4.1. Hospitals and Clinics

15.6.4.4.2. Diagnostic centers

15.6.4.4.3. Research institutes

15.6.4.4.4. Others

15.6.5. South Africa

15.6.5.1. South Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

15.6.5.1.1. Antibiotics

15.6.5.1.2. Cardiac Drugs

15.6.5.1.3. Antiepileptics

15.6.5.1.4. Bronchodilators

15.6.5.1.5. Immunosuppressants

15.6.5.1.6. Anti-cancer drugs

15.6.5.1.7. Psychiatric drugs

15.6.5.1.8. Antiarrythmics

15.6.5.1.9. Others

15.6.5.2. South Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

15.6.5.2.1. Consumables

15.6.5.2.2. Equipment

15.6.5.2.2.1. Immunoassay Analyzers

15.6.5.2.2.2. Chromatography and MS Detectors

15.6.5.2.2.3. Others

15.6.5.2.3. Others

15.6.5.3. South Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

15.6.5.3.1. Fluorescence Immunoassay

15.6.5.3.2. Chemiluminescent Immunoassays

15.6.5.3.3. Radioimmunassay

15.6.5.3.4. Thin Layer Chromatography

15.6.5.3.5. Radio immuno assay

15.6.5.3.6. Enzyme immune assay

15.6.5.3.7. Spectrophotometry and Fluorimetry

15.6.5.3.8. Others

15.6.5.4. South Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

15.6.5.4.1. Hospitals and Clinics

15.6.5.4.2. Diagnostic centers

15.6.5.4.3. Research institutes

15.6.5.4.4. Others

15.6.6. Rest of Middle East & Africa

15.6.6.1. Rest of Middle East & Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

15.6.6.1.1. Antibiotics

15.6.6.1.2. Cardiac Drugs

15.6.6.1.3. Antiepileptics

15.6.6.1.4. Bronchodilators

15.6.6.1.5. Immunosuppressants

15.6.6.1.6. Anti-cancer drugs

15.6.6.1.7. Psychiatric drugs

15.6.6.1.8. Antiarrythmics

15.6.6.1.9. Others

15.6.6.2. Rest of Middle East & Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

15.6.6.2.1. Consumables

15.6.6.2.2. Equipment

15.6.6.2.2.1. Immunoassay Analyzers

15.6.6.2.2.2. Chromatography and MS Detectors

15.6.6.2.2.3. Others

15.6.6.2.3. Others

15.6.6.3. Rest of Middle East & Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

15.6.6.3.1. Fluorescence Immunoassay

15.6.6.3.2. Chemiluminescent Immunoassays

15.6.6.3.3. Radioimmunassay

15.6.6.3.4. Thin Layer Chromatography

15.6.6.3.5. Radio immuno assay

15.6.6.3.6. Enzyme immune assay

15.6.6.3.7. Spectrophotometry and Fluorimetry

15.6.6.3.8. Others

15.6.6.4. Rest of Middle East & Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

15.6.6.4.1. Hospitals and Clinics

15.6.6.4.2. Diagnostic centers

15.6.6.4.3. Research institutes

15.6.6.4.4. Others

15.7. Key Segment for Channeling Investments

15.7.1. By Country

15.7.2. By Drugs

15.7.3. By Products

15.7.4. By Technology

15.7.5. By End Users

16. Latin America Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 - 2027

16.1. Overview

16.1.1. Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn)

16.2. Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

16.2.1. Antibiotics

16.2.2. Cardiac Drugs

16.2.3. Antiepileptics

16.2.4. Bronchodilators

16.2.5. Immunosuppressants

16.2.6. Anti-cancer drugs

16.2.7. Psychiatric drugs

16.2.8. Antiarrythmics

16.2.9. Others

16.3. Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

16.3.1. Consumables

16.3.2. Equipment

16.3.2.1. Immunoassay Analyzers

16.3.2.2. Chromatography and MS Detectors

16.3.2.3. Others

16.3.3. Others

16.4. Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

16.4.1. Fluorescence Immunoassay

16.4.2. Chemiluminescent Immunoassays

16.4.3. Radioimmunassay

16.4.4. Thin Layer Chromatography

16.4.5. Radio immuno assay

16.4.6. Enzyme immune assay

16.4.7. Spectrophotometry and Fluorimetry

16.4.8. Others

16.5. Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

16.5.1. Hospitals and Clinics

16.5.2. Diagnostic centers

16.5.3. Research institutes

16.5.4. Others

16.6. Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country

16.6.1. Brazil

16.6.1.1. Brazil Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

16.6.1.1.1. Antibiotics

16.6.1.1.2. Cardiac Drugs

16.6.1.1.3. Antiepileptics

16.6.1.1.4. Bronchodilators

16.6.1.1.5. Immunosuppressants

16.6.1.1.6. Anti-cancer drugs

16.6.1.1.7. Psychiatric drugs

16.6.1.1.8. Antiarrythmics

16.6.1.1.9. Others

16.6.1.2. Brazil Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

16.6.1.2.1. Consumables

16.6.1.2.2. Equipment

16.6.1.2.2.1. Immunoassay Analyzers

16.6.1.2.2.2. Chromatography and MS Detectors

16.6.1.2.2.3. Others

16.6.1.2.3. Others

16.6.1.3. Brazil Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

16.6.1.3.1. Fluorescence Immunoassay

16.6.1.3.2. Chemiluminescent Immunoassays

16.6.1.3.3. Radioimmunassay

16.6.1.3.4. Thin Layer Chromatography

16.6.1.3.5. Radio immuno assay

16.6.1.3.6. Enzyme immune assay

16.6.1.3.7. Spectrophotometry and Fluorimetry

16.6.1.3.8. Others

16.6.1.4. Brazil Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

16.6.1.4.1. Hospitals and Clinics

16.6.1.4.2. Diagnostic centers

16.6.1.4.3. Research institutes

16.6.1.4.4. Others

16.6.2. Argentina

16.6.2.1. Argentina Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

16.6.2.1.1. Antibiotics

16.6.2.1.2. Cardiac Drugs

16.6.2.1.3. Antiepileptics

16.6.2.1.4. Bronchodilators

16.6.2.1.5. Immunosuppressants

16.6.2.1.6. Anti-cancer drugs

16.6.2.1.7. Psychiatric drugs

16.6.2.1.8. Antiarrythmics

16.6.2.1.9. Others

16.6.2.2. Argentina Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

16.6.2.2.1. Consumables

16.6.2.2.2. Equipment

16.6.2.2.2.1. Immunoassay Analyzers

16.6.2.2.2.2. Chromatography and MS Detectors

16.6.2.2.2.3. Others

16.6.2.2.3. Others

16.6.2.3. Argentina Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

16.6.2.3.1. Fluorescence Immunoassay

16.6.2.3.2. Chemiluminescent Immunoassays

16.6.2.3.3. Radioimmunassay

16.6.2.3.4. Thin Layer Chromatography

16.6.2.3.5. Radio immuno assay

16.6.2.3.6. Enzyme immune assay

16.6.2.3.7. Spectrophotometry and Fluorimetry

16.6.2.3.8. Others

16.6.2.4. Argentina Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

16.6.2.4.1. Hospitals and Clinics

16.6.2.4.2. Diagnostic centers

16.6.2.4.3. Research institutes

16.6.2.4.4. Others

16.6.3. Rest of Latin America

16.6.3.1. Rest of Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs

16.6.3.1.1. Antibiotics

16.6.3.1.2. Cardiac Drugs

16.6.3.1.3. Antiepileptics

16.6.3.1.4. Bronchodilators

16.6.3.1.5. Immunosuppressants

16.6.3.1.6. Anti-cancer drugs

16.6.3.1.7. Psychiatric drugs

16.6.3.1.8. Antiarrythmics

16.6.3.1.9. Others

16.6.3.2. Rest of Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products

16.6.3.2.1. Consumables

16.6.3.2.2. Equipment

16.6.3.2.2.1. Immunoassay Analyzers

16.6.3.2.2.2. Chromatography and MS Detectors

16.6.3.2.2.3. Others

16.6.3.2.3. Others

16.6.3.3. Rest of Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology

16.6.3.3.1. Fluorescence Immunoassay

16.6.3.3.2. Chemiluminescent Immunoassays

16.6.3.3.3. Radioimmunassay

16.6.3.3.4. Thin Layer Chromatography

16.6.3.3.5. Radio immuno assay

16.6.3.3.6. Enzyme immune assay

16.6.3.3.7. Spectrophotometry and Fluorimetry

16.6.3.3.8. Others

16.6.3.4. Rest of Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users

16.6.3.4.1. Hospitals and Clinics

16.6.3.4.2. Diagnostic centers

16.6.3.4.3. Research institutes

16.6.3.4.4. Others

16.7. Key Segment for Channeling Investments

16.7.1. By Country

16.7.2. By Drugs

16.7.3. By Products

16.7.4. By Technology

16.7.5. By End Users

17. Competitive Benchmarking

17.1. Market Share Analysis, 2018

17.2. Global Presence and Growth Strategies

17.2.1. Mergers and Acquisitions

17.2.2. Product Launches

17.2.3. Investments Trends

17.2.4. R&D Initiatives

18. Player Profiles

18.1. Abbot

18.1.1. Company Details

18.1.2. Company Overview

18.1.3. Product Offerings

18.1.4. Key Developments

18.1.5. Financial Analysis

18.1.6. SWOT Analysis

18.1.7. Business Strategies

18.2. Agilent Technologies 

18.2.1. Company Details

18.2.2. Company Overview

18.2.3. Product Offerings

18.2.4. Key Developments

18.2.5. Financial Analysis

18.2.6. SWOT Analysis

18.2.7. Business Strategies

18.3. apDia Group 

18.3.1. Company Details

18.3.2. Company Overview

18.3.3. Product Offerings

18.3.4. Key Developments

18.3.5. Financial Analysis

18.3.6. SWOT Analysis

18.3.7. Business Strategies

18.4. ARK Diagnostics, Inc. 

18.4.1. Company Details

18.4.2. Company Overview

18.4.3. Product Offerings

18.4.4. Key Developments

18.4.5. Financial Analysis

18.4.6. SWOT Analysis

18.4.7. Business Strategies

18.5. Beckman Coulter, Inc.  

18.5.1. Company Details

18.5.2. Company Overview

18.5.3. Product Offerings

18.5.4. Key Developments

18.5.5. Financial Analysis

18.5.6. SWOT Analysis

18.5.7. Business Strategies

18.6. bioMérieux S.A. 

18.6.1. Company Details

18.6.2. Company Overview

18.6.3. Product Offerings

18.6.4. Key Developments

18.6.5. Financial Analysis

18.6.6. SWOT Analysis

18.6.7. Business Strategies

18.7. Bio-Rad Laboratories, Inc

18.7.1. Company Details

18.7.2. Company Overview

18.7.3. Product Offerings

18.7.4. Key Developments

18.7.5. Financial Analysis

18.7.6. SWOT Analysis

18.7.7. Business Strategies

18.8. BioTeZ Berlin Buch GmbH

18.8.1. Company Details

18.8.2. Company Overview

18.8.3. Product Offerings

18.8.4. Key Developments

18.8.5. Financial Analysis

18.8.6. SWOT Analysis

18.8.7. Business Strategies

18.9. BÜHLMANN  

18.9.1. Company Details

18.9.2. Company Overview

18.9.3. Product Offerings

18.9.4. Key Developments

18.9.5. Financial Analysis

18.9.6. SWOT Analysis

18.9.7. Business Strategies

18.10. Chromsystems Instruments & Chemicals GmbH. 

18.10.1. Company Details

18.10.2. Company Overview

18.10.3. Product Offerings

18.10.4. Key Developments

18.10.5. Financial Analysis

18.10.6. SWOT Analysis

18.10.7. Business Strategies

18.11. Exagen, Inc. 

18.11.1. Company Details

18.11.2. Company Overview

18.11.3. Product Offerings

18.11.4. Key Developments

18.11.5. Financial Analysis

18.11.6. SWOT Analysis

18.11.7. Business Strategies

18.12. F. Hoffmann-La Roche Ltd 

18.12.1. Company Details

18.12.2. Company Overview

18.12.3. Product Offerings

18.12.4. Key Developments

18.12.5. Financial Analysis

18.12.6. SWOT Analysis

18.12.7. Business Strategies

18.13. Hamilton Company

18.13.1. Company Details

18.13.2. Company Overview

18.13.3. Product Offerings

18.13.4. Key Developments

18.13.5. Financial Analysis

18.13.6. SWOT Analysis

18.13.7. Business Strategies

18.14. Immundiagnostik AG 

18.14.1. Company Details

18.14.2. Company Overview

18.14.3. Product Offerings

18.14.4. Key Developments

18.14.5. Financial Analysis

18.14.6. SWOT Analysis

18.14.7. Business Strategies

18.15. Quest Diagnostics Incorporated

18.15.1. Company Details

18.15.2. Company Overview

18.15.3. Product Offerings

18.15.4. Key Developments

18.15.5. Financial Analysis

18.15.6. SWOT Analysis

18.15.7. Business Strategies

18.16. Randox Laboratories Ltd. 

18.16.1. Company Details

18.16.2. Company Overview

18.16.3. Product Offerings

18.16.4. Key Developments

18.16.5. Financial Analysis

18.16.6. SWOT Analysis

18.16.7. Business Strategies

18.17. R-Biopharm AG

18.17.1. Company Details

18.17.2. Company Overview

18.17.3. Product Offerings

18.17.4. Key Developments

18.17.5. Financial Analysis

18.17.6. SWOT Analysis

18.17.7. Business Strategies

18.18. SEKISUI CHEMICAL CO., LTD. 

18.18.1. Company Details

18.18.2. Company Overview

18.18.3. Product Offerings

18.18.4. Key Developments

18.18.5. Financial Analysis

18.18.6. SWOT Analysis

18.18.7. Business Strategies

18.19. Siemens Healthcare Private Limited

18.19.1. Company Details

18.19.2. Company Overview

18.19.3. Product Offerings

18.19.4. Key Developments

18.19.5. Financial Analysis

18.19.6. SWOT Analysis

18.19.7. Business Strategies

18.20. THERADIAG 

18.20.1. Company Details

18.20.2. Company Overview

18.20.3. Product Offerings

18.20.4. Key Developments

18.20.5. Financial Analysis

18.20.6. SWOT Analysis

18.20.7. Business Strategies

18.21. Thermo Fisher Scientific Inc

18.21.1. Company Details

18.21.2. Company Overview

18.21.3. Product Offerings

18.21.4. Key Developments

18.21.5. Financial Analysis

18.21.6. SWOT Analysis

18.21.7. Business Strategies

18.22. UTAK

18.22.1. Company Details

18.22.2. Company Overview

18.22.3. Product Offerings

18.22.4. Key Developments

18.22.5. Financial Analysis

18.22.6. SWOT Analysis

18.22.7. Business Strategies

18.23. Other Industry Participants

19. Key Findings

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com